Somatostatin analogues improve health-related quality of life in polycystic liver disease: A pooled analysis of two randomised, placebo-controlled trials

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 591-598

  Neijenhuis, M K ^a   Gevers, T J G ^a   Nevens, F ^b   Hogan, M C ^c   Torres, V E ^c   Kievit, W ^a   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN;

ABDOMINAL CRAMP; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GLOMERULUS FILTRATION RATE; GRANULOMA; HEIGHT ADJUSTED LIVER VOLUME; HEPATOBILIARY PARAMETERS; HUMAN; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; ANALOGS AND DERIVATIVES; CYSTS; DOUBLE BLIND PROCEDURE; LIVER DISEASES; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CYSTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; QUALITY OF LIFE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84938548841     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13301     Document Type: Article

References (38)

1. Hoevenaren IA, Wester R, Schrier RW, et al,. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70.
2. Hogan MC, Masyuk TV, Page LJ, et al,. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-61.
3. Wijnands TF, Neijenhuis MK, Kievit W, et al,. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014; 34: 1578-83.
4. Hogan MC, Abebe K, Torres VE, et al,. Liver involvement in early autosomal dominant polycystic kidney disease. Clin Gastroenterol Hepatol 2015; 13: 154-64.e6.
5. van Keimpema L, Hockerstedt K,. Treatment of polycystic liver disease. Br J Surg 2009; 96: 1379-80.
6. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE,. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-30.
7. Gevers TJ, Drenth JP,. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 101-8.
8. Baber JT, Hiatt JR, Busuttil RW, Agopian VG,. A 20-year experience with liver transplantation for polycystic liver disease: does previous palliative surgical intervention affect outcomes? J Am Coll Surg 2014; 219: 695-703.
9. Gevers TJ, Drenth JP,. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol 2011; 27: 294-300.
10. Caroli A, Perico N, Perna A, et al,. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013; 382: 1485-95.
11. Ruggenenti P, Remuzzi A, Ondei P, et al,. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-16.
12. van Keimpema L, Nevens F, Vanslembrouck R, et al,. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: e1-2.
13. Gevers TJ, Inthout J, Caroli A, et al,. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013; 145: e2.
14. Calvert MJ, Freemantle N,. Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life? J Clin Pharm Ther 2003; 28: 513-21.
15. Calvert MJ, Freemantle N,. Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials. J Clin Pharm Ther 2004; 29: 85-94.
16. Hogan MC, Masyuk TV, Page L, et al,. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-9.
17. Chrispijn M, Nevens F, Gevers TJ, et al,. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35: 266-74.
18. Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP,. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int 2015; 35: 1607-14.
19. Higgins JP, Altman DG, Gotzsche PC, et al,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed) 2011; 343: d5928.
20. Czyzewski L, Sanko-Resmer J, Wyzgal J, Kurowski A,. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant 2014; 19: 576-85.
21. Keown P,. Improving quality of life-the new target for transplantation. Transplantation 2001; 72 (12 Suppl.): S67-74.
22. Ware JE Jr, Kosinski M, et al,. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33 (4 Suppl.): AS264-79.
23. McHorney CA, Ware JE Jr, Raczek AE,. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
24. Ware JE, Kosinski M, Keller SD,. SF-36 Physical and Mental Health Summary Scales: A Users's Manual. Boston, MA: Health Institute, New England Medical Center, 1994.
25. van Keimpema L, Ruurda JP, Ernst MF, van Geffen HJ, Drenth JP,. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg 2008; 12: 477-82.
26. Moons KG, Grobbee DE,. Diagnostic studies as multivariable, prediction research. J Epidemiol Community Health 2002; 56: 337-8.
27. Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP,. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial. J Hepatol 2013; 59: 153-9.
28. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ,. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010; 8: 13.
29. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M,. A comparison of the responsiveness of different generic health status measures in patients with asthma. Qual Life Res 2003; 12: 555-63.
30. Kamphues C, Rather M, Engel S, Schmidt SC, Neuhaus P, Seehofer D,. Laparoscopic fenestration of non-parasitic liver cysts and health-related quality of life assessment. Updates Surg 2011; 63: 243-7.
31. Kirchner GI, Rifai K, Cantz T, et al,. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12: 1268-77.
32. Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM,. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009; 250: 112-8.
33. Gall TM, Oniscu GC, Madhavan K, Parks RW, Garden OJ,. Surgical management and longterm follow-up of non-parasitic hepatic cysts. HPB (Oxford) 2009; 11: 235-41.
34. O'Boyle CA, McGee H, Hickey A, O'Malley K, Joyce CR,. Individual quality of life in patients undergoing hip replacement. Lancet 1992; 339: 1088-91.
35. Torres VE, Chapman AB, Devuyst O, et al,. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-18.
36. Gattone VH 2nd, Wang X, Harris PC, Torres VE,. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-6.
37. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
38. Patrick DL, Deyo RA,. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 (3 Suppl.): S217-32.